JD Supra16h
End of Semaglutide Shortage Means Big Changes for Prescribers and Compounders
On February 21, the FDA announced that the shortage of semaglutide injection products has been resolved. Semaglutide has appeared on the FDA’s ...
Fierce Healthcare3d
FDA declares semaglutide shortage over, spelling end to compounded GLP-1 market, for now
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
Modern Healthcare11h
Hims & Hers pivots as semaglutide shortage ends
Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...
pharmaphorum23h
Compounders cast adrift after semaglutide shortage ends
The end of the official shortage status for semaglutide came as telehealth company Hims & Hers – which has been pushing sales ...
Hosted on MSN1d
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
Hims & Hers Health Inc. (HIMS) stock tumbled over 25% on Friday, extending losses in after-hours trading after the U.S. Food ...
FiercePharma3d
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Hosted on MSN16h
What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle
Compounding pharmacy and IBD 50 newcomer Hims & Hers Health is expected late Monday to report bullish earnings and sales ...